{"paper_id": "5f9db5381c15cb1cd77d11eef019e14829da5b92", "metadata": {"title": "Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients", "authors": [{"first": "Xiaoli", "middle": [], "last": "Wang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Xianghua", "middle": [], "last": "Guo", "suffix": "", "affiliation": {"laboratory": "", "institution": "Capital Medical University", "location": {"settlement": "Beijing", "country": "China"}}, "email": ""}, {"first": "Asso", "middle": [], "last": "Prof", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Qianqian", "middle": [], "last": "Xin", "suffix": "", "affiliation": {"laboratory": "", "institution": "Sinovac Biotech Co., Ltd", "location": {"settlement": "Beijing", "country": "China"}}, "email": ""}, {"first": "Yanhui", "middle": [], "last": "Chu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Capital Medical University", "location": {"settlement": "Beijing, Beijing, Beijing", "country": "China, China, China"}}, "email": ""}, {"first": "Jing", "middle": [], "last": "Li", "suffix": "", "affiliation": {"laboratory": "", "institution": "Sinovac Biotech Co., Ltd", "location": {"settlement": "Beijing", "country": "China"}}, "email": ""}, {"first": "Yang", "middle": [], "last": "Pan", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yingmei", "middle": [], "last": "Feng", "suffix": "", "affiliation": {"laboratory": "", "institution": "Capital Medical University", "location": {"settlement": "Beijing", "country": "China"}}, "email": "yingmeif13@sina.com"}, {"first": "Quanyi", "middle": [], "last": "Wang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Beijing", "middle": [], "last": "Youan", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "Background. COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. The presence of neutralizing antibody was determined with a modified cytopathogenic assay based on live SARS-CoV-2. The dynamics of neutralizing antibody levels at different with different clinical characteristics were analyzed.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "Results. The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), and the antibody level was highest during day 31-40 since onset, and then decreased slightly. Individual differences in changes of antibody levels were observed among 8 representative convalescent patients. In multivariate GEE analysis, patients at age of 31-60 and 61-84 had a higher antibody level than those at age of 16-30 (\u03b2=1.0518, P=0.0152; \u03b2 =1.3718, P=0.0020). Patients with a worse clinical classification had a higher antibody titer (\u03b2=0.4639, P=0.0227).", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "Conclusions. The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Moreover, changes on antibody levels ware individual specific.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "The family Coronaviridae is comprised of large, enveloped, single-stranded, and positive-sense RNA viruses that can infect a wide range of animals and human [1] . Two coronavirus pandemics in human have emerged in the past two decades. Severe acute respiratory syndrome coronavirus (SARS-CoV) was first recognized in 2003, causing a global outbreak [2] . It was followed by another pandemic event in 2012 designated as Middle East respiratory syndrome coronavirus (MERS-CoV) [3] . In December 2019, emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originating in Wuhan, China, has rapidly spread worldwide, and the World white blood cell count were obtained.", "cite_spans": [{"start": 157, "end": 160, "text": "[1]", "ref_id": "BIBREF0"}, {"start": 349, "end": 352, "text": "[2]", "ref_id": "BIBREF1"}, {"start": 475, "end": 478, "text": "[3]", "ref_id": "BIBREF2"}], "ref_spans": [], "section": "Introduction"}, {"text": "The indicators for immunogenicity assessment included seropositivity rate and determination of the geometric mean titer (GMT). The neutralizing antibody titer was calculated by Reed-Muench method on day 5. A titer of 1:4 or higher indicated seropositivity. For calculation of GMT, antibody titers of <1:8, >1:512, and >1:1024 were assigned values of 1:4, 1:(512+512/2), and 1:(1024+1024/2), respectively.", "cite_spans": [], "ref_spans": [], "section": "Immunogenicity Assessment"}, {"text": "The presence of neutralizing antibody was determined with a modified cytopathogenic assay.", "cite_spans": [], "ref_spans": [], "section": "Immunogenicity Assessment"}, {"text": "Serum samples were inactivated at 56\u00b0C for 30 minutes and serially diluted with cell culture medium in two-fold steps. The diluted serums were mixed with a virus suspension of 100 CCID50 in 96-well plates at a ratio of 1:1, followed by 2 hours incubation at 36.5\u00b0C in a 5% CO 2 incubator.", "cite_spans": [], "ref_spans": [], "section": "Immunogenicity Assessment"}, {"text": "1-2 X104 Vero cells were then added to the serum-virus mixture, and the plates were incubated for 5 days at 36.5\u00b0C in a 5% CO 2 incubator. Cytopathic effect (CPE) of each well was recorded under microscopes, and the neutralizing titer was calculated by the dilution number of 50% protective condition.", "cite_spans": [], "ref_spans": [], "section": "Immunogenicity Assessment"}, {"text": "The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.", "cite_spans": [], "ref_spans": [], "section": "Role of the Funding Source"}, {"text": "Of the 70 patients enrolled into this study, 58 were recovered and discharged from hospital ( Table   1 ). The mean age of the patients was 45.1 years (range 16.0-84.0). A total of 58.6% were female.", "cite_spans": [], "ref_spans": [{"start": 94, "end": 103, "text": "Table   1", "ref_id": null}], "section": "Characteristics of the Patients"}, {"text": "Among them, 38 (54.2%) patients were residents or travelled in Wuhan, Hubei. The number of patients having history of cardiovascular disease, diabetes, and hypertension was 2 (2.8%), 5 (7.1%) and 9 (12.9%), respectively. One (1.4%) patient was asymptomatic infected, 22 (31.4%) had mild clinical manifestations, 43 (61.5%) were moderate, and the remaining 4 (5.7%) were in severe condition (1 was inpatients and 3 were convalescent patients). Platelets for inpatients and ", "cite_spans": [], "ref_spans": [], "section": "Characteristics of the Patients"}, {"text": "The seropositivity rate reached up to 100.0% for 117 blood samples at different stages of illness.", "cite_spans": [], "ref_spans": [], "section": "Changes on Antibody Levels with Days since Onset"}, {"text": "The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), of which 52.1% (61/117) had a titer between 1:64 and 1:512 (Table 2) .", "cite_spans": [], "ref_spans": [{"start": 111, "end": 120, "text": "(Table 2)", "ref_id": "TABREF3"}], "section": "Changes on Antibody Levels with Days since Onset"}, {"text": "We analyzed the changes on antibody levels according to the time course since onset ( Table 2 ). The antibody levels according to different time course since onset were significantly different (P=0.0012). The GMT of day 31-40 since onset (1: 271.2, 95% CI, 175.8 to 418.5) reached the highest, and decreased slightly after that time period. Univariate GEE analysis showed that the antibody level during day 31-40 was significantly higher than other phases (Table 4 ). However, multivariate GEE analysis showed that the antibody level during day 31-40 was only higher than day 10-20 (\u03b2= -0.6276, P=0.0201).", "cite_spans": [], "ref_spans": [{"start": 86, "end": 93, "text": "Table 2", "ref_id": "TABREF3"}, {"start": 456, "end": 464, "text": "(Table 4", "ref_id": "TABREF7"}], "section": "Changes on Antibody Levels with Days since Onset"}, {"text": "All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Changes on Antibody Levels with Days since Onset"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 and 4.", "cite_spans": [], "ref_spans": [{"start": 136, "end": 143, "text": "Table 3", "ref_id": "TABREF5"}], "section": "Changes on Antibody Levels with Days since Onset"}, {"text": "Due to the COVID-19 widely spreading around the world, the specific therapeutic agents or vaccines for COVID-19 are urgently needed. We analyzed the neutralizing antibody levels among different classification patient with increased days since onset of symptoms, the results indicated that a significant neutralizing antibody response was observed in convalescent patients, moreover, there were individual differences in changes of antibody levels.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "In the study, typical antibody responses to live viral infection were seen induced in all COVID-19 patients regardless the stage of the disease. Moreover, the immunity levels were already strong enough even at the early stage of illness, with seropositivity rate reaching up to 100.0% at day 10.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "The GMT reached the peak at day 31-40 after onset of symptoms. Even though the GMT had a slightly decreased at day 41-53, the seropositivity rate remained 100.0%. However, the results were different from other study which indicated the titers of antibodies reached their peak at 10 to 15 days after disease onset [12] . After adjusting cofounding factors, multivariate GEE analysis demonstrated that the antibody levels were comparable between day 31-40 and day 41-53 since disease onset. However, the proportion with a titer of 1:512 or above decreased from 52.8% during day 31-40 to 27.6% during day 41-53. Due to the lack of blood samples collected from patients in the later stages of illness, whether and when seropositivity rate declined below 100.0% remained unknown. How long any immunity in patients will last is a key and big unknown problem for safe and effect antiviral treatments and vaccines in the future [13] . For other coronaviruses, immunity after an infection was strong for several months, but then began to wane [14] . Chang [15] indicated that peak IgG titers in all SARS-CoV patients appeared at 1 month or 1 to 3 months after the disease onset, and a drop (4.4-fold on average) in IgG titers was evident between 1 month and 6 months after onset. These studies suggested that it's worthy of further study to analyze antibodies after COVID-19 patients recovered for a longer time.", "cite_spans": [{"start": 313, "end": 317, "text": "[12]", "ref_id": "BIBREF12"}, {"start": 920, "end": 924, "text": "[13]", "ref_id": "BIBREF13"}, {"start": 1034, "end": 1038, "text": "[14]", "ref_id": null}, {"start": 1047, "end": 1051, "text": "[15]", "ref_id": "BIBREF15"}], "ref_spans": [], "section": "Discussion"}, {"text": "All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "The copyright holder for this preprint this version posted April 18, 2020. All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Data are expressed as mean\u00b1SD if not specified.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 27.6 (12.7-47.2) 0.0227 b a P value for GMT was calculated using Kruskal-Wallis rank-sum nonparametric method. b P value for proportions with titer less than 1:64 and 1:512 or above was calculated using trend Chi-square test. c P value for proportions with titer between 1:64 and 1:512 was calculated using Chi-square test.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. # P value for GMT was calculated using Kruskal-Wallis rank-sum nonparametric method.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "The copyright holder for this preprint this version posted April 18, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "The copyright holder for this preprint this version posted April 18, 2020. In the figure, a, b , c, d, e, f, g and h represented the 8 representative convalescent patients. In Figure 2 -A, four patients whose antibody titers showed the obvious increasing trend were included. Figure 2 -B included the other four patients whose antibody titers showed the decreasing trend.", "cite_spans": [], "ref_spans": [{"start": 82, "end": 94, "text": "figure, a, b", "ref_id": null}, {"start": 176, "end": 184, "text": "Figure 2", "ref_id": "FIGREF5"}, {"start": 276, "end": 284, "text": "Figure 2", "ref_id": "FIGREF5"}], "section": "Discussion"}, {"text": "All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "The copyright holder for this preprint this version posted April 18, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "The copyright holder for this preprint this version posted April 18, 2020. . https://doi.org/10.1101/2020.04. 15.20065623 doi: medRxiv preprint ", "cite_spans": [{"start": 110, "end": 143, "text": "15.20065623 doi: medRxiv preprint", "ref_id": null}], "ref_spans": [], "section": "Discussion"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Evidence of the Recombinant Origin and Ongoing Mutations in Severe Acute Respiratory Syndrome 2 (SARS-COV-2)", "authors": [{"first": "J", "middle": ["M"], "last": "Huang", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Jan", "suffix": ""}, {"first": "X", "middle": ["B"], "last": "Wei", "suffix": ""}], "year": null, "venue": "", "volume": "2020", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1101/2020.03.16.993816"]}}, "BIBREF1": {"ref_id": "b1", "title": "Management and Prevention of SARS in China", "authors": [{"first": "N", "middle": [], "last": "Zhong", "suffix": ""}], "year": null, "venue": "Philosophical Transactions of the Royal Society B Biological Sciences", "volume": "359", "issn": "", "pages": "1115--1116", "other_ids": {"DOI": ["10.1098/rstb.2004.1491"]}}, "BIBREF2": {"ref_id": "b2", "title": "Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Challenges in Identifying Its Source and Controlling Its Spread", "authors": [{"first": "L", "middle": [], "last": "Lu", "suffix": ""}, {"first": "Q", "middle": [], "last": "Liu", "suffix": ""}, {"first": "L", "middle": [], "last": "Du", "suffix": ""}], "year": 2013, "venue": "Microbes Infect", "volume": "15", "issn": "", "pages": "625--629", "other_ids": {"DOI": ["10.1016/j.micinf.2013.06.003"]}}, "BIBREF3": {"ref_id": "b3", "title": "WHO. Coronavirus Disease (COVID-2019) Situation Reports", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Assessing the Global Tendency of COVID-19 Outbreak", "authors": [{"first": "Q", "middle": ["H"], "last": "Liu", "suffix": ""}, {"first": "J", "middle": ["K"], "last": "Zhu", "suffix": ""}, {"first": "Z", "middle": ["C"], "last": "Liu", "suffix": ""}], "year": 2020, "venue": "medRxiv", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1101/2020.03.18.20038224"]}}, "BIBREF5": {"ref_id": "b5", "title": "COVID-19: Learning from Experience", "authors": [], "year": 2020, "venue": "The Lancet", "volume": "395", "issn": "", "pages": "30686--30689", "other_ids": {"DOI": ["10.1016/S0140-6736(20"]}}, "BIBREF6": {"ref_id": "b6", "title": "National Health Commission of China. Do Our Best to Prevent and Control the Outbreak of the New Type of Tubular Virus Pneumonia: Report on Situation", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "The Outbreak of SARS-CoV-2 Pneumonia Calls for Viral Vaccines. npj Vaccines", "authors": [{"first": "W", "middle": ["L"], "last": "Shang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yang", "suffix": ""}, {"first": "Y", "middle": ["F"], "last": "Rao", "suffix": ""}], "year": 2020, "venue": "", "volume": "5", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/s41541-020-0170-0"]}}, "BIBREF8": {"ref_id": "b8", "title": "Convalescent Plasma as a Potential Therapy for COVID-19", "authors": [{"first": "L", "middle": [], "last": "Chen", "suffix": ""}, {"first": "J", "middle": [], "last": "Xiong", "suffix": ""}, {"first": "L", "middle": [], "last": "Ba", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Bureau of Disease Control and Prevention, National Health Commission of China", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Convalescent Plasma", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1001/jama.2020.4783"]}}, "BIBREF12": {"ref_id": "b12", "title": "Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and their Implications", "authors": [{"first": "F", "middle": [], "last": "Wu", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Wang", "suffix": ""}, {"first": "M", "middle": [], "last": "Liu", "suffix": ""}], "year": 2020, "venue": "medRxiv", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1101/2020.03.30.20047365"]}}, "BIBREF13": {"ref_id": "b13", "title": "Coronavirus Vaccines: Five Key Questions as Trials Begin", "authors": [{"first": "Ewen", "middle": [], "last": "Callaway", "suffix": ""}], "year": 2020, "venue": "Nature News Explainer", "volume": "579", "issn": "", "pages": "", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-specific Antibody in SARS Patients", "authors": [{"first": "S", "middle": ["C"], "last": "Chang", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Wang", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Huang", "suffix": ""}], "year": 2005, "venue": "Clin Diagn Lab Immunol", "volume": "12", "issn": "12", "pages": "1455--1457", "other_ids": {"DOI": ["10.1128/CDLI.12.12.1455-1457.2005"]}}, "BIBREF16": {"ref_id": "b16", "title": "Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease", "authors": [{"first": "J", "middle": ["J"], "last": "Zhao", "suffix": ""}, {"first": "Q", "middle": [], "last": "Yuan", "suffix": ""}, {"first": "H", "middle": ["Y"], "last": "Wang", "suffix": ""}], "year": 2019, "venue": "", "volume": "2020", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1101/2020.03.02.20030189"]}}, "BIBREF17": {"ref_id": "b17", "title": "Immune Phenotyping Based on", "authors": [{"first": "B", "middle": ["C"], "last": "Zhang", "suffix": ""}, {"first": "X", "middle": ["Y"], "last": "Zhou", "suffix": ""}, {"first": "C", "middle": ["L"], "last": "Zhu", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Neutrophil-to-lymphocyte Ratio and IgG Predicts Disease Severity and Outcome for Patients with COVID-19", "authors": [], "year": 2020, "venue": "medRxiv", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1101/2020.03.12.20035048"]}}, "BIBREF19": {"ref_id": "b19", "title": "Anti-SARS-CoV IgG Response in Relation to Disease Severity of Severe Acute Respiratory Syndrome", "authors": [{"first": "N", "middle": [], "last": "Lee", "suffix": ""}, {"first": "P", "middle": ["K"], "last": "Chan", "suffix": ""}, {"first": "M", "middle": [], "last": "Ip", "suffix": ""}], "year": 2006, "venue": "J Clin Virol", "volume": "35", "issn": "", "pages": "179--184", "other_ids": {"DOI": ["10.1016/j.jcv.2005.07.005"]}}}, "ref_entries": {"FIGREF0": {"text": "convalescent patients were 13.5 and 35.0 10 12 /L, respectively. For the neutralizing antibody test of 1 st sample since onset in this study, the median time was 33.0 days (range 10.0-53.0), and the time of convalescent patients (35.0 days) were longer than inpatients (13.5 days).", "latex": null, "type": "figure"}, "FIGREF1": {"text": "was funded by National Key Research and Development Program of China (2020YFC0842100), Beijing Science and Technology Plan (Z201100005420006), and Beijing Traditional Chinese Medicine (TCM) Science and Technology Development (# BJYAYY-2020YC-02).", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Figure Legends", "latex": null, "type": "figure"}, "FIGREF4": {"text": "of neutralizing antibody titers in 70 patients at different time since onset.", "latex": null, "type": "figure"}, "FIGREF5": {"text": "of neutralizing antibody titers in 8 convalescent COVID-19 patients since onset.", "latex": null, "type": "figure"}, "FIGREF6": {"text": "Figure 2", "latex": null, "type": "figure"}, "TABREF0": {"text": "convalescent patients was 1:212.7(95% CI, 157.5 to 287.3), and was higher than inpatients (1:76.1, 95% CI: 33.5 to 172.9; P=0.0055). Details were listed in", "latex": null, "type": "table"}, "TABREF1": {"text": "Table 1Demographics and clinical characteristics of the COVID-19 patients.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Characteristic </td><td>Total </td><td>Inpatients </td><td>Convalescent patients </td></tr><tr><td>Number of patients </td><td>70 </td><td>12 </td><td>58 </td></tr><tr><td>Male, n (%) </td><td>29 (41.4%) </td><td>4 (33.3%) </td><td>27 (43.1%) </td></tr><tr><td>History of residence or traveling in Wuhan, n(%) </td><td>38 (54.2%) </td><td>5 (41.7%) </td><td>33 (56.9%) </td></tr><tr><td>History of cardiovascular disease, n(%) </td><td>2 (2.8%) </td><td>0 </td><td>2 (3.4%) </td></tr><tr><td>History of diabetes, n(%) </td><td>5 (7.1%) </td><td>0 </td><td>5 (8.6%) </td></tr><tr><td>History of hypertension, n(%) </td><td>9 (12.9%) </td><td>0 </td><td>9 (15.5%) </td></tr><tr><td>Clinical classification, n(%) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Asymptomatic </td><td>1 (1.4%) </td><td>0 (0.0%) </td><td>1 (1.7%) </td></tr><tr><td>Mild </td><td>22 (31.4%) </td><td>3 (25.0%) </td><td>19 (32.8%) </td></tr><tr><td>Moderate </td><td>43 (61.5%) </td><td>8 (66.7%) </td><td>35 (60.3%) </td></tr><tr><td>Severe </td><td>4 (5.7%) </td><td>1 (8.3%) </td><td>3 (5.2%) </td></tr><tr><td>Age (years) , </td><td>45.1\u00b114.2 </td><td>42.7\u00b111.6 </td><td>45.6\u00b114.7 </td></tr><tr><td>Body temperature at admission (\u00b0C) </td><td>37.1\u00b10.7 </td><td>37.0\u00b10.7 </td><td>37.1\u00b10.7 </td></tr><tr><td>Systolic blood pressure (mm Hg) </td><td>126.1\u00b116.9 </td><td>130.2\u00b18.4 </td><td>125.2\u00b117.9 </td></tr><tr><td>Diastolic blood pressure (mm Hg) </td><td>78.4\u00b112.4 </td><td>81.5\u00b110.0 </td><td>77.7\u00b12.8 </td></tr><tr><td>White blood cells (109/L) </td><td>4.3\u00b11.4 </td><td>4.1\u00b11.4 </td><td>4.4\u00b11.4 </td></tr><tr><td>Neutrophil (109/L) </td><td>2.6\u00b11.2 </td><td>2.5\u00b11.2 </td><td>2.6\u00b11.2 </td></tr><tr><td>Lymphocytes (109/L) </td><td>1.3\u00b10.6 </td><td>1.3\u00b10.5 </td><td>1.3\u00b10.6 </td></tr><tr><td>Monocytes (109/L) </td><td>0.3\u00b10.1 </td><td>0.3\u00b10.1 </td><td>0.3\u00b10.1 </td></tr><tr><td>Platelets (1012/L) </td><td>202.0\u00b170.8 </td><td>169.2\u00b150.2 </td><td>209.4\u00b172.4 </td></tr><tr><td>Circulating C-reactive protein (mg/L) </td><td>15.3\u00b120.1 </td><td>7.5\u00b111.8 </td><td>17.2\u00b122.1 </td></tr><tr><td>Days for antibody testing of 1st sample since onset, median (min, max) </td><td>33.0 (10.0, 53.0) </td><td>13.5 (10.0, 22.0) </td><td>35.0 (12.0, 53.0) </td></tr></table></body></html>"}, "TABREF3": {"text": "Seropositivity rates and antibody levels in 117 blood samples at different time since onset.", "latex": null, "type": "table"}, "TABREF5": {"text": "Antibody levels in 70 patients by gender, age, clinical classification, and recovery.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Characteristic </td><td>GMT* (1:) , value(95% CI) </td><td>P # </td></tr><tr><td>Gender </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Male </td><td>168.6(101.2-280.9) </td><td>0.7243 </td></tr><tr><td>Female </td><td>185.6(129.1-266.6) </td><td>\u00a0</td></tr><tr><td>Age, years 16-30 </td><td>71.0(27.7-181.8) </td><td>0.0140 </td></tr><tr><td>31-60 </td><td>200.6(150.4-267.6) </td><td>\u00a0</td></tr><tr><td>61-84 </td><td>220.1(71.8-674.8) </td><td>\u00a0</td></tr><tr><td>Clinical classification </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Asymptomatic or mild </td><td>141.9(79.5-253.2) </td><td>0.2435 </td></tr><tr><td>Moderate or severe </td><td>199.5(141.8-280.5) </td><td>\u00a0</td></tr><tr><td>Recovery or not </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Inpatients </td><td>76.1(33.5-172.9) </td><td>0.0055 </td></tr><tr><td>\u00a0</td><td>Convalescent patients </td><td>212.7(157.5-287.3) </td></tr></table></body></html>"}, "TABREF7": {"text": "Univariate and multivariate GEE analysis of factors associated with antibody levels.All rights reserved. No reuse allowed without permission.", "latex": null, "type": "table"}, "TABREF8": {"text": "The copyright holder for this preprint this version posted April 18, 2020. . https://doi.org/10.1101/2020.04.15.", "latex": null, "type": "table"}, "TABREF9": {"text": ". https://doi.org/10.1101/2020.04.15.20065623 doi: medRxiv preprint", "latex": null, "type": "table"}, "TABREF10": {"text": "Table 4 Univariate and multivariate GEE analysis of factors associated with antibody levels.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>Univariate </td><td>\u00a0</td><td>Multivariate </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Characteristic </td><td>P </td><td>Coefficient </td><td>Standard error </td><td>95% CI </td><td>P </td></tr><tr><td>Gender </td><td>Female vs. male </td><td>0.9426 </td><td>0.0423 </td><td>0.2304 </td><td>-0.4092-0.4938 </td><td>0.8543 </td></tr><tr><td>Age, years </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>31-60 vs. 16-30 </td><td>0.0164 </td><td>1.0518 </td><td>0.4334 </td><td>0.2025-1.9012 </td><td>0.0152 </td></tr><tr><td>\u00a0</td><td>61-84 vs. 16-30 </td><td>0.0061 </td><td>1.3718 </td><td>0.4447 </td><td>0.5002-2.2434 </td><td>0.0020 </td></tr><tr><td>\u00a0</td><td>Moderate or </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Clinical classification </td><td>0.0753 </td><td>0.4639 </td><td>0.2036 </td><td>0.0649-0.8630 </td><td>0.0227 </td></tr><tr><td>\u00a0</td><td>severe vs. mild </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Days since onset </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>10-20 vs. 31-40 </td><td>0.0284 </td><td>-0.6276 </td><td>0.2700 </td><td>-1.1569- -0.0983 </td><td>0.0201 </td></tr><tr><td>\u00a0</td><td>21-30 vs. 31-40 </td><td>0.0410 </td><td>-0.5152 </td><td>0.2765 </td><td>-1.0571-0.0267 </td><td>0.0624 </td></tr><tr><td>\u00a0</td><td>41-53 vs. 31-40 </td><td>0.0152 </td><td>-0.2075 </td><td>0.2616 </td><td>-0.7203-0.3053 </td><td>0.4277 </td></tr></table></body></html>"}}, "back_matter": []}